Safety Profile & Chemical Identity of Melanotan-2 Data from peer-reviewed publications and supplier datasheets Melanotan-2 Chemical Identity Synthetic cyclic heptapeptide analog of -MSH with lactam bridge Asp-Lys Melanotan-2 Documented Tolerance Profile Data from pilot clinical studies and peer-reviewed case reports Published clinical and preclinical data Four peer-reviewed trials and case reports Phase I pilot 1996, Wessells 1998-2000, case reports 2011-2014 2/3 Subjects with measurable pigmentation after 5 low doses of 0,01-0,03 mg/kg SC Doses studied (mg/kg SC) MC4R+ Central erectile function effects documented in double-blind crossover Evaluation method 20 years Cumulative review of Melanotan-I and Melanotan-II development since the University of Arizona Documented steps Case report Melanoma reported after Melanotan-2 injections + use of UV tanning beds Clinical context 3 generations Pharmacological evolution: MT2 (pan-MCR) bremelanotide (MC4R pref.) afamelanotide (MC1R selective) Receptor selectivity Important Notice Search Only Not intended for human consumption
After the injection, clients can immediately return to their daily activities without downtime
These experimental models facilitate the study of new preservation methods, tolerance induction, rejection mechanisms, and novel immunosuppressor therapies [42]
Among the DUBs, ubiquitin-specific protease 13 (USP13) is overexpressed in multiple cancers and is associated with tumorigenesis and poor prognosis
Parasympathetic efferent nerves can transmit neuropeptides and acetylcholine to the islet liver, increasing insulin release and liver NO production through muscarinic receptors and lowering blood sugar
9.9g (330mg x 30 sheets)
